Mergers and Acquisitions

The Irish life sciences and healthcare sector continues to present attractive M&A opportunities, underpinned by ongoing innovation, strategic investment, and robust growth fundamentals. Ireland’s established base of life sciences businesses, supported by a skilled workforce and welldeveloped research and funding infrastructure, positions the country as an attractive destination for corporate acquirers seeking to strengthen their market position.

Looking ahead to 2026, industry consolidation is expected to be a key driver of M&A activity in the life sciences sector, in tandem with the continued growth of private equity activity. Established pharmaceutical and biotechnology companies are anticipated to prioritise acquisitions that deliver access to breakthrough technologies and expand their reach. Among the developments observed in 2025 Irish life sciences M&A, the emergence of a cluster of manufacturing plant and production facility acquisitions is reflective of the wider themes of industry consolidation and strategic investment in physical infrastructure that have recently characterised the sector.

The most significant of these was Merck & Co Inc’s EUR 500 million acquisition of the WuXi Vaccines manufacturing facility in Dundalk, which underscored the continued appetite of global pharmaceutical companies for established Irish production assets. This was accompanied by other facility-level transactions across the sector, including Quasar Medical’s acquisition of Nordson Corporation’s contract manufacturing operations in Galway and Gaelic Laboratories Ltd’s acquisition of Athlone Laboratories Ltd, a manufacturer and supplier of lactam antibiotics. We expect continued investment in physical infrastructure to remain a feature of the Irish life sciences sector in 2026.

International political volatility will continue to pose challenges to M&A activity in 2026. Although US pharmaceutical tariff policy had a more limited impact on the Irish market than initially expected in 2025, developments in US and global trade policies remain a relevant factor for transaction activity, and overall outlook, in the period ahead.

Ireland’s 2025 Programme for Government committed to developing a National Life Sciences Strategy aimed at maintaining the sector’s competitiveness and establishing a coherent, ambitious framework for future growth. Whilst the strategy should provide a longer-term policy roadmap for pharma, biopharma and medtech, its effect on, or indeed its benefits for M&A activity in 2026 remain to be seen. Potential touchpoints include investment screening settings, innovation and reimbursement incentives, and alignment with evolving EU initiatives, but the practical impact on transactions will only become clear once the strategy is finalised and implemented.

It has now been more than a year since the new Irish FDI screening regime entered into force, introducing mandatory notification requirements for qualifying acquisitions of Irish assets or undertakings that may raise national security or public order concerns. While its overall impact on M&A activity remains difficult to assess at this early stage, the limited transparency around the basis on which “no screening required” letters are issued continues to create uncertainty for deal advisers and transaction planning.

A first annual report in respect of the regime was published in May 2026, along with revised guidance on the regime and the relevant procedures. Together, these publications provide the first insight into how Ireland's foreign investment screening regime has operated since it came into force. The report confirms that Ireland’s FDI screening regime is now fully operational, with a high unconditional clearance rate, limited use of in-depth review and timelines operating comfortably within statutory limits. The sectoral profile of screened transactions highlights a clear focus on critical infrastructure and strategically sensitive areas. The revised guidance preserves the Minister’s call-in powers, notwithstanding that these were not exercised in the regime’s first year, underscoring that transactions falling outside the mandatory notification regime may nonetheless be subject to review.

In its first year of operation, a total of 102 notifications were submitted under the regime, and of these 66 were determined not to require mandatory notification and were not subject to formal screening. Two transactions were cleared subject to conditions designed to preserve critical service arrangements. No transactions were prohibited. Of the transactions formally screened, approximately 69% related to critical infrastructure, with the majority of the investments originating in the US and UK.

The outlook for life sciences M&A in 2026 therefore remains positive. Ireland continues to present an attractive proposition for both strategic investors and private equity houses seeking to capitalise on continued development and innovation in the Irish life sciences sector.